GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medigen Biotechnology Corp (ROCO:3176) » Definitions » Price-to-Free-Cash-Flow

Medigen Biotechnology (ROCO:3176) Price-to-Free-Cash-Flow : N/A (As of Jun. 05, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Medigen Biotechnology Price-to-Free-Cash-Flow?

As of today (2024-06-05), Medigen Biotechnology's share price is NT$43.35. Medigen Biotechnology's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 was NT$-4.02. Hence, Medigen Biotechnology's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Medigen Biotechnology's Price-to-Free-Cash-Flow or its related term are showing as below:

During the past 13 years, Medigen Biotechnology's highest Price-to-Free-Cash-Flow Ratio was 20.78. The lowest was 14.63. And the median was 18.59.

ROCO:3176's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 30.345
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Medigen Biotechnology's Free Cash Flow per Share for the three months ended in Mar. 2024 was NT$-0.21. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was NT$-4.02.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 13.10% per year.

During the past 13 years, Medigen Biotechnology's highest 3-Year average Free Cash Flow per Share Growth Rate was 48.10% per year. The lowest was -97.70% per year. And the median was -19.70% per year.


Medigen Biotechnology Price-to-Free-Cash-Flow Historical Data

The historical data trend for Medigen Biotechnology's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medigen Biotechnology Price-to-Free-Cash-Flow Chart

Medigen Biotechnology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 21.35 - -

Medigen Biotechnology Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Medigen Biotechnology's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Medigen Biotechnology's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medigen Biotechnology's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medigen Biotechnology's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Medigen Biotechnology's Price-to-Free-Cash-Flow falls into.



Medigen Biotechnology Price-to-Free-Cash-Flow Calculation

Medigen Biotechnology's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=43.35/-4.024
=N/A

Medigen Biotechnology's Share Price of today is NT$43.35.
Medigen Biotechnology's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-4.02.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Medigen Biotechnology  (ROCO:3176) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Medigen Biotechnology Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Medigen Biotechnology's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Medigen Biotechnology (ROCO:3176) Business Description

Traded in Other Exchanges
N/A
Address
Yuancyu Street, 14F, Building No.3,, Nangang District, Taipei, TWN, 11560
Medigen Biotechnology Corp is a biopharmaceutical company primarily engaged in new drug development, drug discovery, molecular diagnostics, vaccine, and generic drugs. The new drug development business focuses mainly on the clinical stage of drug development and includes PI-88 MUPAFOSTAT for the treatment of liver cancer and OBP-301 treatment using adenovirus targeted to cancer cells only. Drug discovery includes the development of human-native mAbs for therapeutic applications related to infectious diseases. Generic drugs include pharmaceuticals for infectious diseases (antibiotics), contraceptives, nutrition milk powder, vitamin C tablets, dermatologic agents, and eye care products.

Medigen Biotechnology (ROCO:3176) Headlines

No Headlines